Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 2, 1999, Pages 138-142

  Della Torre, Paola ^a   Imondi, Anthony R ^b   Bernardi, Claudio ^a   Podestà, Arturo ^a   Moneta, Donatella ^a   Riflettuto, Mariagrazia ^a   Mazué, Guy ^a  

^a PFIZER INC   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Dexrazoxane; Doxorubicin; Paclitaxel

Indexed keywords

DOXORUBICIN; PACLITAXEL; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; HEART; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE;

EID: 0032987687     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050958     Document Type: Article

References (42)

1. 1. Ali NM, Hamza MR, Abd-Elwarith AM (1998) Doxorubicin/ paclitaxel (DP): an effective combination chemotherapy in visceral (pulmonary and hepatic) metastases of breast cancer. Proc Am Soc Clin Oncol 17: 126a
2. 2. Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E (1996) A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol 23 [Suppl 11]: 16
3. 3. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G, Donati MB (1982) Adriamycin-induced nephrotic syndrome in rats. Lab Invest 46: 16
4. 4. Brouty-Boye D, Kolonias D, Lampidis TJ (1995) Antiproliferative effects of taxol on the human tumor and normal breast cells vs. effects on cardiac cells. Int J Cancer 60: 571
5. 5. Cavaletti G, Tredici G, Massimilliano B, Tazzari S (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133: 64
6. 6. Chen MC, Chiang AA, Chow JM, Yeh KH, Wang CC, Yang CH, Hsu C, Hsu CH, Lu YS, Cheng AL, Whang-Peng J (1998) Paclitaxel in combination with doxorubicin or epirubicin in treating advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 480a
7. 7. Della Torre P, Mazué, Podestà A, Moneta D, Sammartini U, Imondi AR (1999) Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane. Cancer Chemother Pharmacol (in press)
8. 8. Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV (1996) Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23 [Suppl 11]: 23
9. 9. Dunn OI (1964) Multiple comparisons using rank sums. Technometrics 6: 241
10. 10. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13: 2961
11. 11. Gehl J, Boesgaard M, Paaske T, Jensen BV, Dombernowsky P (1996) Paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 23 [Suppl 15]: 35
12. 12. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Carfaceni A, Martini, C, Stefanelli M, Valagussa P, Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688
13. 13. Gianni L, Viganò L, locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906
14. 14. Gianni L, Dombernowsky G, Sledge G, Amadori G, Martin M, Baynes R, Arbuck S, Weil C, Tuck D, Messina M, Winograd B (1998) Cardiac function following combination therapy with taxol (T) and doxorubicin (A) for advanced breast cancer (ABC). Proc Am Soc Clin Oncol 17: 115a
15. 15. Hasinoff BB, Hellmann EH, Herman EH, Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5: 1
16. 16. Herman EH, Ferrans VJ (1983) ICRF-187: reduction of chronic daunomycin and doxorubicin cardiotoxicity in rabbits, beagle dogs and miniature pigs. Drug Exp Clin Res 9: 483
17. 17. Herman EH, El-Hage AN, Ferrans VJ (1987) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92: 42
18. 18. Holmes FA (1994) Combination chemotherapy with taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 5 [Suppl 6]: S23
19. 19. Holmes FA, Valero V. Walters RS, Theriault RL, Booser, D, Vadan-Raj S, Hortobagyi G (1992) Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11: 66a
20. 20. Hortobagyi GN, Holmes FA (1997) Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 24 [Suppl 3]: S4
21. 21. Imondi AR, Della Torre P, Mazué G, Sullivan TM, Robbins TL, Hagerman LM, Podestà A, Pinciroli G (1996) Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats and dogs. Cancer Res 56: 4200
22. 22. Innocenti F, Danesi R, Di Paolo A, Agen A, Nardini D, Bocci G, Del Tacca M (1995) Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 23: 713
23. 23. Kadota T, Chikazawa H, Kondoh H, Ishikawa K, Kawano S, Kuroyanagi K, Hattori N, Sakakura K, Koizumi S, Hiraiwa E (1994) Toxicity studies of paclitaxel. (II) One-month intermittent intravenous toxicity in rats. J Toxicol Sci 19 [Suppl 1]: 11
24. 24. Kadota T, Kondoh H, Chikazawa H, Kuroyanagi K, Hattori N, Ishikawa K, Kawano S, Sakakura K, Koizumi S, Hiraiwa E (1994) Toxicity studies of paclitaxel. (III) Six-month intermittent intravenous toxicity in rats. J Toxicol Sci 19 [Suppl 1]: 35
25. 25. Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47: 583
26. 26. Lenaz L, Page JA (1976) Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3: 111
27. 27. Mazué G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podestà A, Della Torre P, Moneta D (1995) Anthracyclines: a review of general and special toxicity studies. Int J Oncol 7: 713
28. 28. Ferez EA, Buckwalter CA, Reid JP (1996) Combinations of paclitaxel and etoposide in the treatment of lung cancer. Semin Oncol 6 [Suppl 15]: 21
29. 29. Pouna P, Bonoron-Adèle S, Robert J (1996) Evaluation of the cardiotoxicity of anthracyclines associated to taxol with the model of isolated perfused rat heart. Proc Am Assoc Cancer Res 37: 373a
30. 30. Rosell R, Felip E, Massuti B, González larriba JL, Benito D, López Cabrerizo MP, Salamanca O, Camps C, Puerto Pica J (1997) A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer. Semin Oncol 4 [Suppl 12]: 56
31. 31. Rowinsky EK, Casenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
32. 32. Solcia E, Ballerini L, Bellini O, Magrini U, Bertazzoli C, Tosana G, Sala L, Balconi F, Rallo F (1981) Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 67: 461
33. 33. Sledge G, Sparano J, McCaskill-Stevens W, Cobleigh M, Robert N, Baughman C, Neuberg D, Rowinsky E (1993) Pilot trial of alternating taxol and adriamycin for metastatic breast cancer. Proc Am Soc Clin Oncol 12: 85a
34. 34. Sonpavde G, Ansari R, Einhorn L (1998) A phase II trial of bolus doxorubicin and 3-hour paclitaxel as second-line chemotherapy of small cell lung cancer: a Hoosier Oncology Group (HOG) trial. Proc Am Soc Clin Oncol 17: 475a
35. 35. Sparano JA, Speyer J, Gradishar WJ, Wasserbett C, Downey A (1997) Phase I trial of dexrazoxane (Zinecard), doxorubicin (Adriamycin), and escalating doses of paclitaxel (Taxol) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 16: 251a
36. 36. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Jacquotte-Zeleniuch A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione, ICRF-187, against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319: 745
37. 37. Steele RGD, Torrie JH (1960) Analysis of variance I: The one-way classification. In: Steele RGD, Torrie JH (eds) Principles and procedures of statistics. McGraw-Hill, New York p 99
38. 38. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318
39. 39. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15: 1333
40. 40. Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909
41. 41. Viallet J, Tsao MS, Gallant G (1996) Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines. Lung Cancer 1: 93
42. 42. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff A, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710